Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionPharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveDiagnostic and therapeutic biomarkers in pancreaticobiliary malignancyhENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic reviewSystemic therapies for pancreatic cancer--the role of pharmacogeneticsPersonalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerUpdate on the management of pancreatic cancer: surgery is not enoughIdentification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancerDNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cellsBone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosisAlgorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacyHuman concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake.Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeuticsThe Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem CellsEquilibrative nucleoside transporters-A review.Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.Gemcitabine for the treatment of advanced nonsmall cell lung cancerCritical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer.Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer.Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapyHuman equilibrative nucleoside transporter-1 knockdown tunes cellular mechanics through epithelial-mesenchymal transition in pancreatic cancer cells.Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer.High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer.Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cellsFinding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Physiological and pharmacological roles of nucleoside transporter proteins.Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
P2860
Q24273350-701298B9-7446-4B83-B309-FAFAF42237A9Q26752368-0EF0D6AA-3C51-4121-A7EA-32E7FDCC548FQ26767120-2AEF60A2-B996-4416-912E-6E29AD789B05Q26862139-7C15A2FC-C55D-45F8-86F5-720A20BADA76Q27021716-7C52F6D5-1755-4495-8763-1413912D9AB7Q28066268-BF32364A-D1A9-41E3-9FF2-915C78874156Q28075540-AAF2FE0B-F388-47FB-B6B9-06AEA76B110DQ28087060-EF508084-EE74-43FC-9370-3C18DD885084Q28473944-1FEBE722-7006-4654-B19B-A61E2EBC7B02Q28481440-65970A33-7B18-402E-B51F-00E5604655FAQ28483881-8991994E-9089-4E6A-9DE8-969487044779Q28484288-2A779AFA-8C79-4709-9653-2550B36860EBQ28486221-BB1150C9-BB29-41B1-8C07-2CF051489047Q28487715-3327A4AF-1F6F-45DC-B03D-11B979A1D14FQ28550040-ABADDF00-A8FD-43AC-A791-5808B6BCA1D6Q30244329-60F613C2-B2EC-4DC1-93F6-8CB1D54D3CA5Q33336057-723D6C8F-69CF-4C56-AF8F-D508DEF36D73Q33385281-8A3A2007-B3A6-4A78-AF4E-99BA85C87B2FQ33394505-4B9D31A1-1115-4606-ACEF-BDE2E39D1D5BQ33575608-53643B26-AEB9-49BF-91EA-C3B00CE0A416Q33719099-830955BC-1738-46CC-8B62-AD144DA15E17Q33915997-F0075CBE-345A-48E0-914A-F8E43CD880E1Q34014091-496ED6FA-A84D-40D4-98BE-CC2C5D9ABB7DQ34067856-283B2CC9-DB66-422F-A5A2-BA3925694807Q34127857-756BE584-FA29-4649-991E-BF080B429B62Q34177223-67018562-D622-4A26-8DFA-92EEF728A62EQ34205171-7DC35F2F-14E1-48D2-A65F-4F9BF6F10310Q34234101-813ECCEB-C2CC-4EA1-8C55-BABF5E85A075Q34237421-639AD620-566A-4019-80DE-B4332F817170Q34254837-1A3E4920-8291-4FC7-8EEF-79C56B5BED80Q34283650-351FECD2-6B74-4B5B-99B6-095E320E9F2BQ34337500-3A99E6E7-23DE-43E2-AA0F-5ED741EB44ADQ34414547-A96FBC58-2B04-4AB0-8EF0-58CFBE70C3DBQ34479270-9D10BDCE-9AC3-4CB6-8D2E-F9C345F69966Q34507964-86B6BD29-B27E-4080-93A1-AE03651DAE97Q34609029-75B31297-F3F6-44B7-9B59-6E5FE005F5B0Q34621614-C739A020-F212-4037-91EA-431A169F2769Q34646772-60EE26B6-4BE7-49A4-A061-8D8DB7F45BACQ34792283-2078C6F6-CF75-4E60-92DD-DBFBDDBCDF59Q34792522-7A194B45-4B84-44D4-AE72-2C17DAC05F90
P2860
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Transcription analysis of huma ...... ents treated with gemcitabine.
@ast
Transcription analysis of huma ...... ents treated with gemcitabine.
@en
type
label
Transcription analysis of huma ...... ents treated with gemcitabine.
@ast
Transcription analysis of huma ...... ents treated with gemcitabine.
@en
prefLabel
Transcription analysis of huma ...... ents treated with gemcitabine.
@ast
Transcription analysis of huma ...... ents treated with gemcitabine.
@en
P2093
P50
P1433
P1476
Transcription analysis of huma ...... ients treated with gemcitabine
@en
P2093
Cinzia Orlandini
Daniela Campani
Franco Mosca
Marco Del Chiaro
Mario Del Tacca
Mauro Iannopollo
Sara Nannizzi
Sergio Ricci
Valentina Mey
P304
P356
10.1158/0008-5472.CAN-05-4203
P407
P577
2006-04-01T00:00:00Z